PHILIPPINE HEART ASSOCIATION

1108, 11th Floor East Tower, PSE Centre

Exchange Road, Ortigas Center, Pasig City
Tel. No.: (+632) 470.5525
Fax No.: (+632) 687.7797
E-mail: phil.heart@yahoo.com
secretariat@philheart.org
Website: www.philheart.org
 MESSAGE

Every year, the field of Cardiology grows by leaps and

bounds. As knowledge in the discipline accumulates, clinical
applicability and practice patterns are guided through
formulation of guidelines, consensus statements and
recommendations from international and local associations,
experts’ groups and key opinion leaders. These are quite
OFFICERS 2010-2011 essential if standards are to be set for management, research
and training purposes.
ELEANOR A. LOPEZ, MD President Heretofore, validated goals and outcome expectations
ISABELO V. ONGTENGCO JR., MD Vice President
ROMEO B. CRUZ VP for Finance
dictate on the directions we take, the strategies we employ and
ANDRE S. KAHN VP for External Affairs the options we choose. Yet, such standards or goals become
SATURNINO P. JAVIER, MD Secretary meaningless and inappropriate if they are not tempered with
EUGENE B. REYES, MD Treasurer the realities we confront everyday – legislation, socio-economic
JOEL M. ABANILLA, MD Director restrictions, accessibility, unavailability of drug and technology,
TIMOTHY C. DY, MD Director
MA. CONSOLACION DOLOR-TORRES, MD Director
among others.
MARIA TERESA B. ABOLA, MD Immediate Past President A compleat clinician integrates all these into a cohesive
body of approaches and policies. This annual convention seeks
to focus on all these and more. Welcome and we wish you all
42nd ANNUAL PHA CONVENTION an intellectually rewarding scientific activity.
ORGANIZING COMMITTEE

SATURNINO P. JAVIER, MD Over-all Chair

EUGENE B. REYES, MD Chair, Scientific Committee
JOEL M. ABANILLA, MD Chair, Sessions Committee EUGENE B. REYES, MD SATURNINO P. JAVIER, MD
ISABELO V. ONGTENGCO JR., MD Chair, Registration Chair, Scientific Committee Chair, Organizing Committee
TIMOTHY C. DY, MD Chair, Exhibits & Physical Arrangement
MA. CONSOLACION DOLOR-TORRES, MD Chair, Socials
MARIA TERESA B. ABOLA, MD Chair, Protocol
PEDRO P. SAN DIEGO JR., MD Chair, Information Technology
ERLYN C. DEMERRE, MD Chair, Publication
ELEANOR A. LOPEZ, MD
President

1
REGISTRATION EXHIBITS
All participants must register to be able to attend the different scientific sessions Booth exhibits will be featured during the convention which will provide and update
including the company sponsored satellite meetings, visit exhibits, and participate concerning products, medical equipment and research.
in the fellowship and other social events. Advance registration is encouraged to
avail of discounted fees and help avoid delays at the time of the scientific sessions. SOCIALS AND CEREMONIES
(Please use the Advance Registration Form included in this program). Deadline for All registered delegates are invited to participate in the Opening and Closing
receipt of Advance Registration is March 30, 2011. If you cannot pre-register by Ceremonies, Fellowship Dinner and other social activities.
that date, you may do so at Edsa Shangri-La Hotel from May 25 to 27, 2011.
ATTIRE
REGISTRATION FEES
Smart casual attire in all social and scientific functions. For the Convocation,
CATEGORY ADVANCE REGULAR DAILY Opening and Closing Ceremonies, semi-formal attire is requested.
(Until March 30) (After March 30)
PHA members* P 1,200 P 1,500 700** BADGES
Non-members 1,400 1,700 700** Your badge will be provided in the convention kit. The badge will serve as your
Residents 1,000 1,200 700** pass to the various activities during the convention. Lost badges can be replaced
Fellows-in-Training 1,000 1,200 700** for a fee at the on-site registration area.
Medical Students 1,000 1,200 700** THE PHA-DR. FRANCISCO F. TANGCO
Nurses / Technicians 1,000 1,200 700** YOUNG INVESTIGATOR’S AWARD
PHA family members 600 700 700** This award aims to stimulate local research in cardiology by giving incentives to
Exhibitors 600 800 700** young researchers and also serves to honor the memory of the late Dr. Francisco F.
Tangco who had always helped, guided and stimulated the growth of the medical
*Annual membership fee is not included in registration fee
profession and of cardiology.
**Daily registration fee does not include convention kit
The contest is open to all research papers in cardiology presented during the annual
REGISTRATION SCHEDULES PHA meeting. The paper must be original, not previously published, and must have
DATE TIME been done locally. To qualify for this award, the senior author and presentor must
May 25, 2011 8:00 a.m. – 5:00 p.m. not be over 35 years old at the time of the presentation.
May 26, 2011 8:00 a.m. – 5:00 p.m.
May 27, 2011 8:00 a.m. – 12:00 noon PHA MOST OUTSTANDING TRAINING FELLOW IN CARDIOLOGY
This award is open to all Fellows in a formal cardiology training program.
HOTEL ACCOMMODATION
The criteria for judging are :
A considerable number of rooms has been blocked at the convention site, Edsa
1. Must have at least three (3) years of residency training in internal medicine
Shangri-La Hotel, Crowne Plaza Galleria Manila, Oakwood Premier Joy-Nostalg Center
and three (3) years training in cardiology in an instituition accredited by the
Manila and The Richmonde Hotel. Rooms are available on a first-come-first-served
Specialty Board of Adult Cardilogy.
basis. All hotel bookings should be coursed through the PHA Secretariat.
2. Must have passed the written and practical examinations given by the
Above rates are subject to 10 % service charge, 12% VAT and applicable local tax. Philippine College of Cardiology Specialty Board.
Advance hotel registration requires 50% deposit. Payment must be made in 3. Must possess outstanding performance during the training program.
Philippine currency addressed to the hotel. 4. Must present a scientific paper during the Annual Convention and Scientific
Meeting of the Philippine Heart Association.
CANCELLATION 5. Must be officially nominated by the Chief/Head/Chairman of Cardiology
Department/Section of the accredited institution. The nomination must be
Written cancellations of registration will be accepted until April 15, 2011 with a
endorsed by two other members of the consultant staff in cardiology of the
refund of 50% of the amount paid. No refund will be possible for cancellation
institution.
received after April 15, 2011.
6. Deadline of Nomination: March 31, 2011.
2 3
 THE PHA-SERVIER AWARD
FOR MOST OUTSTANDING RESEARCH IN CARDIOLOGY
1. Servier Philippines, Inc., through the Philippine Heart Association, will fund a
PHA-Servier Award for Most Outstanding Research in Cardiology.
2. The purpose of such an award will be to stimulate research work in Cardiology in the
Philippine setting by giving due recognition to outstanding research accomplishments
done by the fellows of the Philippine Heart Association.
3. Candidates for the award must be:
a. A Filipino citizen.
b. The main author must be a Fellow of the PHA in good standing.
4. The research entry should fulfill the following:
a. Original and not previously published in a local/international scientific journal.
b. Not previousy presented in any national/international forum.
c. The research papers must have been started and completed after graduating
from training.
d. Done in the Philippines.
5. All submitted papers using a standard set of criteria will be pre-screened by the
members of the Research Commitete. All those which passed the screening process
will automatically enter the contest.
6. The PHA Scientific and Research Committee shall require the following for
submission:
a. Five (5) original copies of the fully accomplished research work without
the name of author(s) and institution of origin if any.
b. Name of author(s) and institution of origin if any, in a separate sealed
envelope to be provided by the PHA.
7. An independent 5-member Board of Judges shall be chosen by the Scientific and
Research Committee with the concurrence of the PHA Board of Directors.
8. The Board of Judges and the members of the PHA Board and the Scientific Research
Committee of the PHA are disqualified from the contest.
9. The contest proper shall be held during the PHA Annual Convention and the award
shall be presented during its Closing Ceremonies.
10. The PHA-Servier Awards for Most Outstanding Research in Cardiology shall
consist of:
a. A grant of SEVENTYFIVE THOUSAND PESOS (P75,000.00) to the winning
candidate who will also receive an appropriate commemoration of the award
(plaque, medallion, trophy, etc.).
b. A grant of THIRTY THOUSAND PESOS (P30,000.00) to the first runner-up.
c. A grant of TWENTY THOUSAND PESOS (P20,000.00) to the second runner-up.
12. The sponsor, Servier Philippines, Inc. shall bear all the administrative costs of the
award, including cost of committee meetings, plaques, posters, announcements, etc.
13. The PHA shall circularize to all PHA accredited training institutions and local PHA
chapters the details of the annual award. Servier Philippines, Inc. may likewise
promote the annual award directly to PHA members, training centers and affiliate
and component subspecialty societies, provided said direct communications or
promotions have prior notation of the PHA.
12. The right to first publication of the winning research paper belong to the Philippine
Heart Association.
4
COLLEGE AWARDS
1. LOYALTY AWARD
This award is given to a Past President of the PHA of any of its Chapters who has not
been a member of the Board of Directors for at least five (5) years. He/She must have
continuously served the Association in various capacities contributing to the
furtherance of its goals like:
a. Regular attendance to annual conventions and business meetings
b. Participation in the activities of the Association as:
- speaker- committee member- resource person
- lay activities - fund raising campaigns
- or any outstanding activity related to the Association
2. DISTINGUISHED SERVICE AWARD
This award is given to any physician, scientist or lay person or institution who by
individual/concerted effort, has made profound contributions to cardiology through
delivery of services and the furtherance of the goals of the Association in the national
or international level for at least ten (10) years. They may include the following:
a. Has served the Association as chairman or member in any of the major
committees/councils.
b. Has been an active members of the Boards of Directors or Chapter during
the past ten (10) years.
3. DISTINGUISHED TEACHER AWARD
This award is given to a fellow of the College who, because of his/her demonstrated
abilities as outstanding teacher, is considered to have made major contributions to
cardiology through the teaching and mentoring of students at the undergraduate/post
doctoral levels. At least two (2) of the following criteria must also fulfilled:
1. Member of the academe for at least ten (10) years with a rank
of assistant professor or higher.
2. Active member of cardiology section of a PHA duly accredited institution.
3. Contributor or editor of books and journals in cardiology.
4. Recognized as outstanding teacher in the institution where she/he belong.
4. DISTINGUISHED SCIENTIST AWARD
This award is given to an individual who:
1. Should have published original papers in reputable local and/or
international journals.
2. May have contributed significant knowledge in the field of
cardiovascular diseases.
3. May have pioneered in diagnostic and therapeutic procedures in the
management of cardiovascular disease.
5. DISTINGUISHED FELLOW AWARD
This is the most prestigious and highest awards among the college awards and is
conferred to a Fellow of the college who has received any two of the college awards and
is qualified to receive a third award. In lieu of the third award, the distinguished Fellow
Award is given.
You may send in your nominees to the Secretariat for final deliberation by the Awards
Committee on or before March 31, 2011.
Members of the PHA Board of Directors cannot be proponents or nominees for any of
the awards.
The Awards Committee reserves the right to choose the final nominees.
5
 TOPICS TOPICS
SIMULTANEOUS SYMPOSIA SIMULTANEOUS SYMPOSIA

A. Congenital Heart Disease

1. ACE Inhibitors in Congenital Heart Disease H. Cardiovascular Anesthesia and Critical Care
2. Role of drugs in Pulmonary Hypertension from Congenital Heart Disease 1. Critical Care Updates for the General Cardiologist
3. Anatomy of Congenital Heart Defects: Imaging of choice 2. Hemodynamic Monitoring in “Rural” care setting
4. Hybrid surgery in Hypoplastic Left Heart Syndrome 3. State of the Art in Shock Management

B. CPR I. Cardiac Catheterizations and Interventions

1. The 2010 International Guidelines on Resuscitation: Highlights, Major
Changes and Key Recommendations
2. Celebrating 50 years of CPR: A Look back at the Past History, a Peek
into the Present Updates, a Gaze into the Future Recommendations
3. Compliance with Evidence Based Resuscitation Guidelines: Do they J.
improve outcome?
C. RF-RHD
1. Revisiting the use of Prophylaxis on RF-RHD (Pedia and Adult
Practices) K.
2. A Patient with Coronary Aneurysm: Approach to Management
3. Hypertension in the Young (Nephro/Pedia)
D. Hypertension
1. Hypertensive patients with Obesity, Diabetes and/or Dyslipidemia – L.
Approach in the Management
2. Sexual Dysfunction and Hypertension – Approach in the Management
3. Treatment of Hypertensive patients with Ischemic Heart Disease
E. Cardiac Rehabilitation
1. How to Implement Clinical Based Cardiac Rehabilitation – Guidelines
2. Pitfalls and Difficulties of Cardiac Events in the Philippines – The
Realities
3. New Modalities and Innovations in Cardiac Rehabilitation M. Echocardiography
F. Electrophysiology
1. Prevention of Thromboembolism in Atrial Fibrillation - Getting with the
Guidelines
2. Primary Prevention of Sudden Cardiac Death in Patients with Heart
Disease: Guideline-based device therapy
3. Primary prevention of Sudden Cardiac Death in Inherited Arrhythmogenic
Diseases
N. Congestive Heart Failure
G. Coronary Artery Disease
1. Thienopyridines in ACS: Guidelines, New Doses, New Agents, and
Interactions with other Drugs
2. The role of metabolic agents (trimetazidine, Ibavradine, L-carnitine,
and Co-enzyme Q) in Cardiovascular Disease?
3. Current recommendation for anti-platelets in the primary prevention
of cardiovascular events in patients with diabetes and CKD?
O. Cardiomyopathy
1. Sending the MI patient to the LAB.
2. PCI or CABG for Multivessel CAD and or Diabetes
3. Adjunctive Pharmacology
Stroke and PVD
1. Anti-coagulation 101: practical points not to be missed
2. VTE prophylaxis 101:
3. The real score on Contraceptive pills?
Preventive Cardiology
1. Impact of Mew Trialsd and Evidences on Lipid Guidelines
2. Obesity in the Philippines: Is there a Guideline?
3. The Burden of Cardiovascular Disease in Philippines
Women’s Cardiovascular Health
Dilemmas in Pregnancy with Cardiovascular Disease
Physiologic Changes in Pregnancy
Panel Discussion:
Pregnancy in Rheumatic Heart Disease
Pregnancy in Congenital Heart Disease
Postpartum Cardiomyopathy
Arrhythmic pregnant
1. Echocardiographic Assessment of the Right Heart in Adults: What do
the Guidelines mean for your Patient?
2. New Technologies & Imaging Modalities in the Evaluation of Patients
with Cardiomyopathy & Pericardial Disease
3. Assessing a Patient with Systolic Heart Failure and Diastolic Heart
Failure
4. Prosthetic Valve Assessment: What do the Guidelines mean?
1. Chemotherapy & Heart Failure:A dialogue Between Cardiologist &
Oncologist
2. Diabetic Cardiomyopathy : Mechanisms, Diagram and Treatment
- A Cardiologist & Endocrinologist Perspectives
3. Hemodialysis vs Ultrafiltration in the Treatment of volume overload in
decompensated HF - Cardiologist & Nephrologist Points of View
1. Impact of PAH guidelines in the Real Filipino setting
2. PAH Prevalence in the Philippines
3. PAH from the Multispecialty point of view

6 7
 ABSTRACT PREPARATION INSTRUCTION ABSTRACT
1. The abstract must be submitted on the enclosed Abstract Form.
2. The abstract must be contained in the space provided and use a type size no
smaller than 10 point.
3. Type title in Bold using upper and lower case letters and not to exceed 200
words.
4. Type complete names of authors (M.D. or other principal degrees not
necessary). List responsible institutions and their respective cities and
provinces
5. Leave a blank line after author(s)/institution(s) and before abstract text.
6. Abstract text should include purpose, methods, results, and conclusions. Do
not include references or credits. Simple tables or graphs may be included if
they fit within the space allowed.
7. Use standard abbreviations. Place special or unusual abbreviations in
parentheses after the full word the first time it appears. A limit of five
additional special abbreviations may be used in each abstract.
8. Please avoid printing on lines of abstract box.
9. Deadline for submission of abstracts: on or before March 15, 2011 and the
final manuscripts on or before March 31, 2011
10. Accepted oral abstracts will be presented during a special session the exact
date of which will be announced at a later date. Posters will be presented
during a special poster presentation session and during breaks in the exhibit
hall.
11. Abstract accepted for presentation will be published in the April to June Issue
of the Philippine Journal of Cardiology.
12. Submit the original abstract (unfolded) by first class or overnight mail to:
Philippine Heart Association Secretariat
1108, 11th Floor East Tower, PSE Centre
Exchange Road, Ortigas Center, Pasig City
13. The complete manuscript should be in a Compact Disc (CD) or Digital
Versatile Disc(DVD) and one (1) hardcopy using MS-Word Application.
Author should provide, and identify as , 5-8 keywords or short phrases that
will assist a reseacher in identifying an information material.
14. Indicate the required information on the authors as follows:

NAME OF AUTHOR/S

NAME OF PRESENTOR

INSTITUTION

TEL NO. FAX NO. E-MAIL ADDRESS

8 9
 ABSTRACT CONTENTS REGISTRATION FORM

CAPITALIZE ENTIRE ABSTRACT TITLE FAMILY NAME GIVEN NAME MIDDLE NAME
Author. Underline only presenting author’s name.Institution, City
INSTITUTION/COMPANY
OBJECTIVES: State main question or study objective(s) or
hypothesis.
ADDRESS ZIPCODE
DESIGN: Describe study design. Indicate if randomized, blinded
and if temporal direction, retrospective or prospective.
TELEPHONE No. FAX No. E-MAIL ADDRESS
SETTING: Indicate the study setting (hospital, clinic, community).
Also include the level of clinical care (primary or tertiary); private
practice or institutional. PRC No. PMA No.

PATIENTS/PARTICIPANTS: State selection procedures, entry

REGISTRATION FEE
criteria and numbers of participants entering and finishing the
study. Please check:
ADVANCE REGULAR DAILY
INTERVENTIONS, IF ANY: Describe the essential features of an (Until March 30, 2011) (After March 30, 2011)
intervention/exposure, including the method and duration of
administration. PHA member* P 1,200 1,500 700**

MAIN OUTCOME MEASURE(S): The primary study outcome Non-member 1,400 1,700 700**
measure should be indicated as planned before the data collection
Resident 1,000 1,200 700**
began. Fellow-in-Training 1,000 1,200 700**
Medical Student 1,000 1,200 700**
RESULTS: Describe measurements that are not evident from the Nurse/Technician 1,000 1,200 700**
nature of the main results and indicate any blinding. If possible,
the results should be accompanied by confidence intervals (most PHA family member 600 700 700**
often the 95% interval) and the exact level of statistical
significance. For comparative studies, confidence intervals should Exhibitor 600 800 700**
relate to the differences between groups. Absolute values should
be indicated when risk changes or effect sizes are given.
* Annual membership fee is not included in registration fee
**Daily registration fee does not include convention kit.
CONCLUSIONS: State only those conclusions of the study that are
directly supported by data, along with their clinical application
(avoiding generalization) or whether additional study is required
Signature of Registrant Date
before the information should be used in usual clinical settings.
11
10